NO3014707T3 - - Google Patents
Info
- Publication number
- NO3014707T3 NO3014707T3 NO15745380A NO15745380A NO3014707T3 NO 3014707 T3 NO3014707 T3 NO 3014707T3 NO 15745380 A NO15745380 A NO 15745380A NO 15745380 A NO15745380 A NO 15745380A NO 3014707 T3 NO3014707 T3 NO 3014707T3
- Authority
- NO
- Norway
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361920819P | 2013-12-26 | 2013-12-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO3014707T3 true NO3014707T3 (no) | 2018-01-06 |
Family
ID=52293273
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO15745380A NO3014707T3 (no) | 2013-12-26 | 2015-06-23 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US9914731B2 (no) |
| EP (2) | EP3309160A1 (no) |
| JP (1) | JP2017500362A (no) |
| KR (1) | KR20160110390A (no) |
| CN (1) | CN106029661B (no) |
| AU (1) | AU2014370186A1 (no) |
| BR (1) | BR112016015057A2 (no) |
| CA (1) | CA2934667A1 (no) |
| CL (1) | CL2016001604A1 (no) |
| DK (1) | DK3087070T3 (no) |
| EA (2) | EA201890061A3 (no) |
| ES (1) | ES2654931T3 (no) |
| HU (1) | HUE037579T2 (no) |
| IL (1) | IL246311A0 (no) |
| MX (1) | MX2016008445A (no) |
| NO (1) | NO3014707T3 (no) |
| PH (1) | PH12016501232A1 (no) |
| PL (1) | PL3087070T3 (no) |
| PT (1) | PT3087070T (no) |
| SG (1) | SG11201605207PA (no) |
| SI (1) | SI3087070T1 (no) |
| WO (1) | WO2015100117A1 (no) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2992586A1 (en) * | 2015-07-16 | 2017-01-19 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
| CN106467541B (zh) | 2015-08-18 | 2019-04-05 | 暨南大学 | 取代喹诺酮类衍生物或其药学上可接受的盐或立体异构体及其药用组合物和应用 |
| CN106543145B (zh) * | 2016-10-28 | 2019-07-19 | 山西医科大学 | c-Met激酶抑剂3-(4-氟苯基)嘧啶酮-5-甲酸酰胺衍生物、制备方法与应用 |
| US10703757B2 (en) | 2016-12-23 | 2020-07-07 | Plexxikon Inc. | Compounds and methods for CDK8 modulation and indications therefor |
| US11168090B2 (en) | 2017-01-18 | 2021-11-09 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors |
| CN111372925B (zh) * | 2017-11-24 | 2022-09-02 | 南京明德新药研发有限公司 | 作为c-MET/AXL抑制剂的尿嘧啶类化合物 |
| US11524963B2 (en) | 2018-01-18 | 2022-12-13 | Array Biopharma Inc. | Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors |
| JP6997876B2 (ja) | 2018-01-18 | 2022-02-04 | アレイ バイオファーマ インコーポレイテッド | Ｒｅｔキナーゼ阻害剤としての置換ピラゾリル［４，３－ｃ］ピリジン化合物 |
| TWI802635B (zh) | 2018-01-18 | 2023-05-21 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡咯并[2,3-d]嘧啶化合物 |
| EP3842425B1 (en) * | 2018-08-24 | 2024-05-22 | TransThera Sciences (Nanjing), Inc. | Novel quinoline derivative inhibitor |
| UY38349A (es) | 2018-08-30 | 2020-03-31 | Array Biopharma Inc | Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met |
| EP3849986B1 (en) | 2018-09-10 | 2022-06-08 | Array Biopharma, Inc. | Fused heterocyclic compounds as ret kinase inhibitors |
| KR20210142154A (ko) | 2019-03-21 | 2021-11-24 | 옹쎄오 | 암 치료를 위한 키나제 억제제와 조합된 dbait 분자 |
| CN110467616B (zh) * | 2019-07-01 | 2021-12-21 | 江西科技师范大学 | 含杂芳基取代哒嗪酮结构的三唑并吡嗪类化合物的制备及应用 |
| CN110330479A (zh) * | 2019-07-19 | 2019-10-15 | 南京华威医药科技集团有限公司 | 一种用作axl抑制剂的抗肿瘤化合物及其用途 |
| US20220324869A1 (en) * | 2019-09-06 | 2022-10-13 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Compound having axl and c-met kinase inhibitory activity, preparation thereof and application thereof |
| WO2021089791A1 (en) | 2019-11-08 | 2021-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| JPWO2023286719A1 (no) * | 2021-07-13 | 2023-01-19 | ||
| IT202100022682A1 (it) * | 2021-09-01 | 2023-03-01 | Luigi Frati | Derivati pirimidinici e loro uso nel trattamento di tumori |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20020506A1 (es) * | 2000-08-22 | 2002-07-09 | Glaxo Group Ltd | Derivados de pirazol fusionados como inhibidores de la proteina cinasa |
| US7173031B2 (en) * | 2004-06-28 | 2007-02-06 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| US7547782B2 (en) * | 2005-09-30 | 2009-06-16 | Bristol-Myers Squibb Company | Met kinase inhibitors |
| MX2008011220A (es) * | 2006-03-07 | 2008-09-11 | Array Biopharma Inc | Compuestos de pirazol heterobiciclicos y metodos de uso. |
| BRPI0720169A2 (pt) * | 2006-12-12 | 2013-12-24 | Takeda Pharmaceutical | Composto ou um sal do mesmo, prodroga, agente farmacêutico, método para a profilaxia ou tratamento de câncer, e, uso do composto |
| EP1972628A1 (en) | 2007-03-21 | 2008-09-24 | Schwarz Pharma Ag | Indolizines and aza-analog derivatives thereof as CNS active compounds |
| EP2320907A4 (en) | 2008-08-05 | 2012-09-05 | Merck Sharp & Dohme | THERAPEUTIC COMPOUNDS |
| SG181781A1 (en) * | 2009-12-31 | 2012-07-30 | Hutchison Medipharma Ltd | Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor |
| PE20140378A1 (es) * | 2011-02-25 | 2014-03-28 | Irm Llc | Compuestos y composiciones como inhibidores de la trk |
| CN102827186A (zh) * | 2011-06-16 | 2012-12-19 | 中国科学院上海药物研究所 | 一类吡啶并五元杂环衍生物及其制备方法和用途 |
| JP6001072B2 (ja) * | 2011-08-10 | 2016-10-05 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | ピリド−ピリミジン誘導体 |
| EP2758055A1 (en) * | 2011-09-19 | 2014-07-30 | F.Hoffmann-La Roche Ag | Combination treatments comprising c-met antagonists and b-raf antagonists |
| SG10201510307WA (en) * | 2011-11-14 | 2016-01-28 | Cephalon Inc | Uracil derivatives as axl and c-met kinase inhibitors |
| WO2013180949A1 (en) * | 2012-05-27 | 2013-12-05 | Ning Xi | Substituted quinoline compounds and methods of use |
-
2014
- 2014-12-18 EP EP17196014.9A patent/EP3309160A1/en not_active Withdrawn
- 2014-12-18 SI SI201430533T patent/SI3087070T1/en unknown
- 2014-12-18 DK DK14824711.7T patent/DK3087070T3/en active
- 2014-12-18 ES ES14824711.7T patent/ES2654931T3/es active Active
- 2014-12-18 MX MX2016008445A patent/MX2016008445A/es unknown
- 2014-12-18 CA CA2934667A patent/CA2934667A1/en not_active Abandoned
- 2014-12-18 AU AU2014370186A patent/AU2014370186A1/en not_active Abandoned
- 2014-12-18 WO PCT/US2014/071040 patent/WO2015100117A1/en active Application Filing
- 2014-12-18 BR BR112016015057A patent/BR112016015057A2/pt not_active IP Right Cessation
- 2014-12-18 EP EP14824711.7A patent/EP3087070B1/en not_active Not-in-force
- 2014-12-18 EA EA201890061A patent/EA201890061A3/ru unknown
- 2014-12-18 KR KR1020167019605A patent/KR20160110390A/ko not_active Application Discontinuation
- 2014-12-18 SG SG11201605207PA patent/SG11201605207PA/en unknown
- 2014-12-18 PL PL14824711T patent/PL3087070T3/pl unknown
- 2014-12-18 CN CN201480075903.4A patent/CN106029661B/zh not_active Expired - Fee Related
- 2014-12-18 EA EA201691164A patent/EA029757B1/ru not_active IP Right Cessation
- 2014-12-18 US US15/108,400 patent/US9914731B2/en not_active Expired - Fee Related
- 2014-12-18 JP JP2016542956A patent/JP2017500362A/ja active Pending
- 2014-12-18 PT PT148247117T patent/PT3087070T/pt unknown
- 2014-12-18 HU HUE14824711A patent/HUE037579T2/hu unknown
-
2015
- 2015-06-23 NO NO15745380A patent/NO3014707T3/no unknown
-
2016
- 2016-06-19 IL IL246311A patent/IL246311A0/en unknown
- 2016-06-21 CL CL2016001604A patent/CL2016001604A1/es unknown
- 2016-06-22 PH PH12016501232A patent/PH12016501232A1/en unknown
-
2018
- 2018-01-24 US US15/879,175 patent/US20180148447A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DK3087070T3 (en) | 2017-12-04 |
| JP2017500362A (ja) | 2017-01-05 |
| EA201890061A2 (ru) | 2018-05-31 |
| AU2014370186A1 (en) | 2016-07-14 |
| HUE037579T2 (hu) | 2018-09-28 |
| ES2654931T3 (es) | 2018-02-15 |
| EA201691164A1 (ru) | 2016-12-30 |
| EA201890061A3 (ru) | 2018-09-28 |
| WO2015100117A1 (en) | 2015-07-02 |
| PL3087070T3 (pl) | 2018-03-30 |
| EA029757B1 (ru) | 2018-05-31 |
| KR20160110390A (ko) | 2016-09-21 |
| AU2014370186A2 (en) | 2016-07-21 |
| CL2016001604A1 (es) | 2017-05-26 |
| US9914731B2 (en) | 2018-03-13 |
| IL246311A0 (en) | 2016-08-02 |
| SI3087070T1 (en) | 2018-01-31 |
| CN106029661A (zh) | 2016-10-12 |
| SG11201605207PA (en) | 2016-07-28 |
| PT3087070T (pt) | 2018-01-30 |
| CA2934667A1 (en) | 2015-07-02 |
| US20180148447A1 (en) | 2018-05-31 |
| PH12016501232A1 (en) | 2016-08-15 |
| US20160318929A1 (en) | 2016-11-03 |
| EP3309160A1 (en) | 2018-04-18 |
| BR112016015057A2 (pt) | 2017-08-08 |
| CN106029661B (zh) | 2017-11-03 |
| MX2016008445A (es) | 2016-10-28 |
| EP3087070A1 (en) | 2016-11-02 |
| EP3087070B1 (en) | 2017-11-08 |